STAGE III HEPATOCELLULAR CARCINOMA AJCC V8
Clinical trials for STAGE III HEPATOCELLULAR CARCINOMA AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE III HEPATOCELLULAR CARCINOMA AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE III HEPATOCELLULAR CARCINOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New combo aims to shrink liver tumors before surgery
Disease control OngoingThis study tests whether combining regorafenib (a drug that blocks cancer cell growth) with durvalumab (an immunotherapy that helps the immune system attack cancer) can shrink tumors in people with high-risk liver cancer. About 4 adults with early-stage but high-risk liver cancer…
Matched conditions: STAGE III HEPATOCELLULAR CARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: Academic and Community Cancer Research United • Aim: Disease control
Last updated May 26, 2026 04:25 UTC
-
New combo therapy shows promise for inoperable liver cancer
Disease control OngoingThis early-phase trial studies the safety and effectiveness of two immunotherapy drugs (durvalumab and tremelimumab) given after a targeted radiation procedure for patients with advanced liver cancer that cannot be removed by surgery. The treatment aims to help the immune system …
Matched conditions: STAGE III HEPATOCELLULAR CARCINOMA AJCC V8
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 26, 2026 04:23 UTC
-
Engineered immune cells take on Hard-to-Treat liver cancer
Disease control TerminatedThis early-stage trial tests a new treatment for people with advanced liver cancer that has not responded to standard therapies. The treatment uses the patient's own immune cells, modified in a lab to recognize and attack cancer cells carrying a specific protein called GPC3. The …
Matched conditions: STAGE III HEPATOCELLULAR CARCINOMA AJCC V8
Phase: PHASE1 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated May 22, 2026 13:53 UTC
-
New combo shows promise against tough liver cancer
Disease control OngoingThis study tests a new drug called pevonedistat, given alone or with standard chemotherapy, in 40 adults with advanced bile duct cancer that has spread or cannot be removed. The goal is to see if the combination can shrink tumors or stop them from growing. Participants must have …
Matched conditions: STAGE III HEPATOCELLULAR CARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 19, 2026 11:59 UTC
-
Tailored radiation doses aim to shrink liver tumors
Disease control OngoingThis study tests whether giving a personalized dose of radiation directly to liver tumors can improve treatment results for people with advanced liver cancer that cannot be removed by surgery. About 42 participants will receive a customized radiation plan based on their individua…
Matched conditions: STAGE III HEPATOCELLULAR CARCINOMA AJCC V8
Phase: NA • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 11, 2026 20:48 UTC
-
New combo therapy shows promise for HIV patients with advanced cancer
Disease control OngoingThis early-phase trial is testing the safety of combining two cancer drugs—nivolumab and cabozantinib—in people with HIV who have advanced solid tumors. The study includes 8 participants with various cancers that have spread. The goal is to see if the combination can shrink or st…
Matched conditions: STAGE III HEPATOCELLULAR CARCINOMA AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 11, 2026 20:38 UTC